×
About 2,445 results

ALLMedicine™ Acid Phosphatase Center

Research & Reviews  944 results

Tartrate-resistant acid phosphatase 5 promotes pulmonary fibrosis by modulating β-caten...
https://doi.org/10.1038/s41467-021-27684-9
Nature Communications; Hu Y, Wang Q et. al.

Jan 12th, 2022 - Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with limited therapeutic options. Tartrate-resistant acid phosphatase 5 (ACP5) performs a variety of functions. However, its role in IPF remains unclear. Here, we demonstrate...

Shell water-soluble matrix protein from oyster shells promoted proliferation, different...
https://doi.org/10.1016/j.ijbiomac.2021.12.168
International Journal of Biological Macromolecules; Feng X, Jiang S et. al.

Jan 10th, 2022 - Matrix protein is secreted by the membrane of bivalve shellfish to and used to regulate shell biomineralization. In this study, we extracted water-soluble matrix protein (WSMP) from oyster shells to investigate its effects on osteogenic differenti...

Combination of metformin and exercise alleviates osteoarthritis in ovariectomized mice ...
https://doi.org/10.1016/j.bone.2021.116323
Bone Li H, Gou Y et. al.

Jan 7th, 2022 - To evaluate and compare the effects of the combined intervention of metformin and exercise on the degeneration of cartilage and subchondral bone in a mouse model of osteoarthritis (OA) induced by estrogen deficiency and obesity. 56 female 3-month-...

Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and th...
https://doi.org/10.1039/d1fo02944d
Food & Function; Sun Y, Wang F et. al.

Jan 6th, 2022 - In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs). The results indicated ...

A novel adiponectin receptor agonist (AdipoAI) ameliorates type 2 diabetes-associated p...
https://doi.org/10.1111/jre.12969
Journal of Periodontal Research; Wu X, Sun Y et. al.

Jan 6th, 2022 - Type 2 diabetes (T2D)-associated periodontitis is severe and refractory in many cases. Considered an inflammatory disease, T2D predisposes to periodontitis by increasing whole-body inflammation. One mechanism of increased inflammation is thatT2D i...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  3 results

Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT02793219

Oct 30th, 2017 - Castration-resistant prostate cancer (CRPC) develops serial treatment resistance and is considered incurable. It is a largely indolent disease, which would give the body time to mount an effective immune response. CRPC is therefore potentially wel...

APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT00027599

Feb 11th, 2013 - OBJECTIVES: I. Determine the efficacy of APC8015 (Provenge) and bevacizumab, in terms of decline in prostate-specific antigen (PSA) value and effect on PSA doubling time, in patients with progressive prostate cancer. II. Determine any immune respo...

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
https://clinicaltrials.gov/ct2/show/NCT00005947

Nov 1st, 2010 - Objectives: I. Compare the time to progression, time to development of disease-related pain, and incidence of grade 3 or worse treatment-related adverse events in patients with asymptomatic metastatic hormone refractory adenocarcinoma of the prost...

see more →

News  29 results

Immune Correlates May Indicate Responsiveness to Ipilimumab in mCRPC
https://www.onclive.com/view/immune-correlates-may-indicate-responsiveness-to-ipilimumab-in-mcrpc

Oct 6th, 2021 - Sumit Subudhi, MD, PhD A subset of patients with metastatic castration-resistant prostate cancer (mCRPC) who have low tumor mutational burden (TMB) may benefit from checkpoint inhibition with ipilimumab (Yervoy) if the tumor has a high density of...

Vogelzang Disputes 'Weak' Guideline Rating for Sipuleucel-T
https://www.onclive.com/view/vogelzang-disputes-weak-guideline-rating-for-sipuleucel-t

Oct 6th, 2021 - Nicholas J. Vogelzang, MD In a recent guideline for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC), the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) shared their thoughts on the imp...

Sipuleucel-T Helps ADT Boost Prostate Cancer Immunity
https://www.onclive.com/view/sipuleucel-t-helps-adt-boost-prostate-cancer-immunity

Oct 6th, 2021 - Emmanuel S. Antonarakis, MBBCh Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC) who face a high risk of developing metastases, a s...

Sipuleucel-T Soon Available to Patients in Europe and Beyond
https://www.onclive.com/view/sipuleucel-t-soon-available-to-patients-in-europe-and-beyond

Oct 6th, 2021 - An immunotherapy drug for the treatment of prostate cancer, approved in the US in 2010, will soon be available in Europe, the maker of the medicine, Dendreon Corporation, announced today. Sipuleucel-T (Provenge) initially will be available in Ger...

Need for Dynamic, Predictive Biomarkers Remains Pressing
https://www.onclive.com/view/need-for-dynamic-predictive-biomarkers-remains-pressing

Oct 6th, 2021 - Joshua M. Lang, MD Assistant Professor of Medicine University of Wisconsin Carbone Cancer Center The last 10 years have shown tremendous advances in the development of targeted therapeutics for patients with advanced cancer. Ranging from a...

see more →